Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Sep 22, 2022 Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit View Press Release Sep 13, 2022 Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference View Press Release Aug 11, 2022 Abeona Therapeutics Reports Second Quarter 2022 Financial Results View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
